(INNE)
ZORÉCIMÉRAN(INNF)
ZORECIMERAN(INND)
ZORECIMERAN(INNC)
MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING A FULLLENGTH CODON-OPTIMISED PRE-FUSION STABILIZED CONFORMATION VARIANT (K986P AND V987P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; NC_045512.2) SPIKE (S) GLYCOPROTEIN, FLANKED BY 5' AND 3' UNTRANSLATED REGIONS; THE 3' UNTRANSLATED REGION COMPRISES A PART OF THE HUMAN ALPHA GLOBIN GENE 3' UTR SEQUENCE ELEMENT, A SYNTHETIC POLY(A) TAIL AND A POLY(C)-RICH SEQUENCE FOLLOWED BY A HISTONE STEM LOOP SEQUENCE AS A 3' TAIL; REC. LIST 85(WHO)
R9515 MRNA ENCODES THE FULL LENGTH SPIKE (S) SARS-COV-2 VIRUS PROTEIN WITH THE INTRODUCTION OF TWO PROLINE SUBSTITUTIONS TO STABILIZE THE S PROTEIN IN PRE-FUSION CONFOR9515 MRNA ENCODES THE FULL LENGTH SPIKE (S) SARS-COV-2 VIRUS PROTEIN WITH THE INTRODUCTION OF TWO PROLINE SUBSTITUTIONS TO STABILIZE THE S PROTEIN IN PRE-FUSION CONFORMATION WHICH IS EXPRESSED UPON UPTAKE INTO CELLS. R9515 IS FORMULATED WITH LIPIDS TO FORM THE CVNCOV OR CV07050101. THIS RESULTS IN A FINISHED DRUG PRODUCT THAT IS A LIPID NANO PARTICLE (LNP)-FORMULATED MRNA PRODUCT DESIGNED TO EXPRESS A SARS-COV-2 VIRUS ANTIGEN UPON UPTAKE INTO CELLSRMATION WHICH IS EXPRESSED UPON UPTAKE INTO CELLS. R9515 IS FORMULATED WITH LIPIDS TO FORM THE CVNCOV OR CV07050101. THIS RESULTS IN A FINISHED DRUG PRODUCT THAT IS A LIPID NANO PARTICLE (LNP)-FORMULATED MRNA PRODUCT DESIGNED TO EXPRESS A SARS-COV-2 VIRUS ANTIGEN UPON UPTAKE INTO CELLS(RD)
RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-AM)-CAPPED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 PRE-FUSION SPIKE GLYCOPROTEIN (986-PROLINE,987-PROLINE)-SPECIFYING 3'-TAILED MESSENGER R9515), INNER SALT(PCHC)
ZORECIMERANUM(INN)